BioAtla Q1 2024 Earnings Report $1.18 -0.13 (-9.92%) (As of 12/18/2024 05:44 PM ET) Earnings HistoryForecast BioAtla EPS ResultsActual EPS-$0.48Consensus EPS -$0.57Beat/MissBeat by +$0.09One Year Ago EPSN/ABioAtla Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABioAtla Announcement DetailsQuarterQ1 2024Date5/14/2024TimeN/AConference Call ResourcesPress ReleaseBCAB Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by I want to send you my Cash Calendar (Ad)This Calendar reveals the EXACT dates that — if everything goes right — anyone can target cash payouts of $125, $415, and even $1,665. (With just a $1,000 starting stake!) Granted, there were smaller wins and those that did not work out and we cannot promise future returns or against losses, but these payouts don’t require any special knowledge or skills. Anyone can set them up with just three clicks in their brokerage account. And the money can be deposited in their account the very next morning after opening the trade. Again, I want to send this Cash Calendar to you completely FREE. All you have to do is join me for my free Cash Calendar training right here. You don’t want to miss this. There is a very special bonus surprise for everyone who attends. Reserve your seat. BioAtla Earnings HeadlinesBioAtla presents data on mecbotamab vedotin in advanced NSCLCDecember 17 at 10:41 AM | markets.businessinsider.comBioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingDecember 16 at 8:00 AM | globenewswire.comWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."December 19, 2024 | DTI (Ad)BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingDecember 10, 2024 | globenewswire.comMichael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 tradesNovember 14, 2024 | msn.comBioAtla: Strong Financials and Promising Clinical Progress Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comSee More BioAtla Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email. Email Address About BioAtlaBioAtla (NASDAQ:BCAB), a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.View BioAtla ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
